Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.75 |
| ▸ | NPC1 | O15118 | 7/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.73 |
| ▸ | HPGD | P15428 | 1/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.71 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | AGER | Q15109 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | SCD | O00767 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2664747 | 0.86 | RAB9A (0.77) | RAB9ANPC1SMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL28478360 | 0.86 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2HSD17B10PKM | |
| SCHEMBL2753283 | 0.82 | RAB9A (0.92) | RAB9ANPC1SMN1; SMN2HSD17B10PKM | |
| SCHEMBL13212117 | 0.82 | ALDH1A1 (0.75) | PKMLMNAMEN1KMT2ARECQL | |
| SCHEMBL4295195 | 0.81 | RAB9A (0.76) | RAB9ANPC1SMN1; SMN2HSD17B10ADORA2A | |
| SCHEMBL706414 | 0.81 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2HPGDHSD17B10 | |
| SCHEMBL3223685 | 0.81 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2HSD17B10ADORA2A | |
| SCHEMBL6227032 | 0.80 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2HSD17B10ADORA2A | |
| SCHEMBL4290771 | 0.79 | NPC1 (0.79) | RAB9ANPC1SMN1; SMN2HSD17B10ADORA2A | |
| SCHEMBL4296512 | 0.78 | ADORA2A (0.76) | RAB9ANPC1SMN1; SMN2HSD17B10ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150105433-A1 | TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM | THE UAB RESEARCH FOUNDATION | 2015-04-16 | — | — | US | disclosed |
| US-20150105433-A1 | TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM | THE UAB RESEARCH FOUNDATION | 2015-04-16 | — | — | US | disclosed |
| US-20120065247-A1 | MODULATING IRES-MEDIATED TRANSLATION | DISCOVERYBIOMED, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065247-A1 | MODULATING IRES-MEDIATED TRANSLATION | DISCOVERYBIOMED, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| WO-2010111653-A2 | MODULATING IRES-MEDIATED TRANSLATION | THE UAB RESEARCH FOUNDATION (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065247-A1 | MODULATING IRES-MEDIATED TRANSLATION | EIF2AK2, EIF4EBP1, EIF4E | RAB9A 2106/4885NPC1 2519/4885SMN1; SMN2 1695/4885 |
| US-20150105433-A1 | TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM | EIF2AK2, RPS25, RPL35 | RAB9A 2752/4885NPC1 859/4885SMN1; SMN2 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.